Voyager Therapeutics: Advance multiple preclinical programs towards clinical trials, with the goal of filing three IND applications within the next 24-months VY-FXN01 program

Voyager Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Highlights. CAMBRIDGE, Mass., March 15, 2017 (GLOBE NEWSWIRE) . Corporate Goals and 2017 Financial Guidance

Voyager remains committed to becoming the leading gene therapy company focused on severe diseases of the CNS with expertise in discovery, development, manufacturing and commercialization of gene therapy products for people living with these devastating diseases. The significant accomplishments achieved during 2016 provide a solid foundation for continued progress during 2017 and beyond, as measured by the planned achievements of the following corporate goals and 2017 financial guidance:

-Advance multiple preclinical programs towards clinical trials, with the goal of filing three IND applications within the next 24-months for the VY-SOD101, VY-HTT01, and VY-FXN01 (for Friedreich’s ataxia) programs.